Nedaplatin
- Generic Name
- Nedaplatin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C2H8N2O3Pt
- CAS Number
- 95734-82-0
- Unique Ingredient Identifier
- 8UQ3W6JXAN
- Background
Nedaplatin is a second generation platinum analog . It is less nephrotoxic than Cisplatin but has proven equally effective. It was approved for use in Japan in 1995.
- Indication
Used in the treatment of non-small cell lung cancer, small cell lung cancer, oesophygeal cancer, and head and neck cancers .
- Associated Conditions
- -
- Associated Therapies
- -
Weekly Cisplatin or Nedaplatin Concurrent With Intensity-modulated Radiation Therapy in Nasopharyngeal Carcinoma
- First Posted Date
- 2014-11-25
- Last Posted Date
- 2014-12-08
- Lead Sponsor
- He Xia
- Target Recruit Count
- 120
- Registration Number
- NCT02301208
Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2014-03-17
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 290
- Registration Number
- NCT02088515
- Locations
- 🇨🇳
Hunan Xiangya Hospital, Changsha, Hunan, China
🇨🇳Nanjing Military General Hospital, Nanjing, Jiangsu, China
🇨🇳Shanghai Chest hospital, Shanghai, Shanghai, China
Temozolomide, Nedaplatin, Vincristine, and Radiotherapy as First-line Treatment in Newly Diagnosed Primary CNS Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2012-11-28
- Last Posted Date
- 2013-03-12
- Lead Sponsor
- Rongjie Tao
- Target Recruit Count
- 16
- Registration Number
- NCT01735747
- Locations
- 🇨🇳
Neurosurgery, Shandong Cancer Hospital and Institute, Jinan, Shandong, China
Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma
- First Posted Date
- 2012-02-28
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 402
- Registration Number
- NCT01540136
- Locations
- 🇨🇳
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Intensity-modulated Radiation Therapy Combined With Cisplatin or Nedaplatin Chemotherapy in Nasopharyngeal Carcinoma
- First Posted Date
- 2010-12-23
- Last Posted Date
- 2011-01-20
- Lead Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Target Recruit Count
- 20
- Registration Number
- NCT01265147
- Locations
- 🇨🇳
Daping Hospital, Chong Qing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.